BEX2 is poor prognostic factor and required for cancer stemness in gastric cancer.

Akihiro Yasumoto,Haruna Fujimori,Mai Mochizuki,Rie Shibuya-Takahashi,Mao Nakamura-Shima,Norihisa Shindo,Kazunori Yamaguchi,Daisuke Fukushi,Yuta Wakui,Takahiro Sugai,Wataru Iwai,Makoto Abue,Ikuro Sato,Kennichi Satoh,Yu Katayose,Jun Yasuda,Chikashi Shibata,Keiichi Tamai

Biochemical and biophysical research communications（2023）

Cited 0|Views25

No score

Abstract

Gastric cancer is the fifth most common malignancy worldwide. However, targeted therapy for advanced gastric cancer is still limited. Here, we report BEX2 (Brain expressed X-linked 2) as a poor prognostic factor in two gastric cancer cohorts. BEX2 expression was increased in spheroid cells, and its knockdown decreased aldefluor activity and cisplatin resistance. BEX2 was found to upregulate CHRNB2 (Cholinergic Receptor Nicotinic Beta 2 Subunit) expression, a cancer stemness-related gene, in a transcriptional manner, and the knockdown of which also decreases aldefluor activity. Collectively, these data are suggestive of the role of BEX2 in the malignant process of gastric cancer, and as a promising therapeutic target.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined